Shattuck Labs, Inc. (STTK) Spending and interest coverage
- R&D / revenue · 12 months: Value 3932.00%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 853.20%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 3932.00% | Research and development expense / revenue. Period ending 2026-06-30. $39.32M ÷ $1.00M × 100 ≈ 3932.00% |
| Stock-based compensation / revenue · 12 months | 853.20% | Share-based compensation / revenue. Period ending 2026-06-30. $8.53M ÷ $1.00M × 100 ≈ 853.20% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 39.32M USD | Research and Development Expense |
| Revenue | 1.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.53M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -55.79M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.32M | $1.00M | $8.53M | $-55.79M | (m) | 3932.00% | 853.20% | (m) | (m) |
| 2026-03-31 | $36.30M | $1.00M | $7.69M | $-52.66M | (m) | 3630.00% | 768.90% | (m) | (m) |
| 2025-12-31 | $35.27M | $1.00M | $7.00M | $-51.51M | (m) | 3527.30% | 699.50% | (m) | (m) |
| 2025-09-30 | $41.61M | $1.00M | $7.24M | $-57.78M | (m) | 4161.30% | 723.90% | (m) | (m) |
| 2025-06-30 | $50.31M | $3.00M | $8.02M | $-64.98M | (m) | 1678.58% | 267.50% | (m) | (m) |
| 2025-03-31 | $60.87M | $4.61M | $8.79M | $-74.91M | (m) | 1321.45% | 190.88% | (m) | (m) |
| 2024-12-31 | $67.21M | $5.72M | $9.55M | $-80.57M | (m) | 1174.81% | 166.86% | (m) | (m) |
| 2024-09-30 | $67.04M | $6.43M | $9.34M | $-79.88M | (m) | 1041.85% | 145.08% | (m) | (m) |
| 2024-06-30 | $74.94M | $4.12M | $8.54M | $-90.56M | (m) | 1817.19% | 207.18% | (m) | (m) |
| 2024-03-31 | $73.91M | $2.71M | $7.73M | $-90.34M | (m) | 2722.17% | 284.75% | (m) | (m) |
| 2023-12-31 | $74.31M | $1.66M | $6.94M | $-91.96M | (m) | 4484.61% | 418.77% | (m) | (m) |
| 2023-09-30 | $80.97M | $1.33M | $6.99M | $-99.28M | (m) | 6074.27% | 524.53% | (m) | (m) |
| 2023-06-30 | $75.62M | $859.00K | $6.95M | $-95.91M | (m) | 8803.38% | 809.20% | (m) | (m) |
| 2023-03-31 | $80.38M | $709.00K | $6.63M | $-100.82M | (m) | 11336.95% | 935.40% | (m) | (m) |
| 2022-12-31 | $82.90M | $652.00K | $6.46M | $-103.33M | (m) | 12714.57% | 991.10% | (m) | (m) |
| 2022-09-30 | $77.22M | $30.34M | $5.99M | $-67.81M | (m) | 254.51% | 19.73% | (m) | (m) |
| 2022-06-30 | $73.49M | $32.03M | $5.61M | $-60.16M | (m) | 229.47% | 17.50% | (m) | (m) |
| 2022-03-31 | $65.41M | $27.75M | $5.80M | $-57.01M | (m) | 235.75% | 20.90% | (m) | (m) |
| 2021-12-31 | $56.56M | $30.02M | $5.47M | $-45.27M | (m) | 188.44% | 18.21% | (m) | (m) |
| 2021-09-30 | $50.14M | $1.28M | $4.89M | $-66.53M | (m) | 3914.36% | 381.58% | (m) | (m) |
| 2021-06-30 | $46.81M | $1.82M | $3.86M | $-60.78M | (m) | 2577.64% | 212.33% | (m) | (m) |
| 2021-03-31 | $39.68M | $9.23M | $2.27M | $-42.59M | (m) | 430.03% | 24.62% | (m) | (m) |
| 2020-12-31 | $37.48M | $9.93M | $1.27M | $-36.93M | (m) | 377.32% | 12.74% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $29.22M | $9.89M | $461.00K | $-25.07M | (m) | 295.52% | 4.66% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |